Heat Biologics to Present at the Genitourinary Cancers Symposium
14 févr. 2017 08h00 HE
|
Heat Biologics
DURHAM, N.C., Feb. 14, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against...
Heat Biologics to Present at NobleCon13
24 janv. 2017 08h00 HE
|
Heat Biologics
DURHAM, N.C., Jan. 24, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against...
Heat Biologics to Present at Biotech Showcase 2017 Conference in San Francisco
05 janv. 2017 08h00 HE
|
Heat Biologics
DURHAM, N.C., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against...
Heat Biologics Appoints Jeff Hutchins, Ph.D., as Chief Scientific Officer
04 janv. 2017 08h00 HE
|
Heat Biologics
Industry veteran, Dr. Hutchins, to advance Heat’s platform technologies and pursue immunotherapy combinationsFormer CSO Taylor Schreiber, M.D., Ph.D., to chair Heat’s Scientific Advisory Board and...
Heat Biologics Presents Topline HS-110/Nivolumab Combination Lung Cancer Results
06 déc. 2016 08h20 HE
|
Heat Biologics
Reports Positive Data on Primary Endpoint with Positive Safety Data Overall Survival Compares Favorably with Single-Agent Nivolumab Management to host a call on Thursday, December 8th, at 8:30 a.m....
Heat Biologics Presents Topline HS-410 Phase 2 Bladder Cancer Results at the Society of Urological Oncology Annual Meeting
30 nov. 2016 17h27 HE
|
Heat Biologics
DURHAM, N.C., Nov. 30, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq:HTBX), a leader in the development of gp96-based immunotherapies that are designed to activate a patient’s immune system...
Heat Biologics to Present Topline HS-110/Nivolumab Combination Phase Ib Lung Cancer Results at the International Society for the Study of Lung Cancer Annual Meeting
17 nov. 2016 07h00 HE
|
Heat Biologics
DURHAM, N.C., Nov. 17, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq:HTBX), a leader in the development of gp96-based immunotherapies that are designed to activate a patient’s immune system...
Heat Biologics to Present Topline HS-410 Phase II Bladder Cancer Results at the Society of Urological Oncology Annual Meeting
16 nov. 2016 07h00 HE
|
Heat Biologics
DURHAM, N.C., Nov. 16, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq:HTBX), a leader in the development of gp96-based immunotherapies that are designed activate a patient’s immune system...
Heat Biologics Presents ComPACT Preclinical Data at the Society for Immunotherapy of Cancer Annual Meeting
14 nov. 2016 07h00 HE
|
Heat Biologics
Enhanced Tumor Rejection in Colorectal Cancer Mouse Model Combined Synergistically with PD1 and PD-L1 Checkpoint Inhibitors DURHAM, N.C., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc....
Heat Biologics Provides Corporate Update and Reports Third Quarter 2016 Financial Results
10 nov. 2016 16h46 HE
|
Heat Biologics
DURHAM, N.C., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient’s immune system against...